What question did this study set out to answer?

This study aims to evaluate the safety and efficacy of adding atogepant to onabotulinumtoxinA for chronic migraine treatment.

April 10, 2026Cephalalgia

Safety, tolerability, and efficacy of atogepant added to onabotulinumtoxinA for the preventive treatment of chronic migraine: A phase 3, multicenter, 24-week, open-label study

View Full Paper

Ask AI

Bookmark

Authors

Phase 3 open-label study shows combined therapy reduces chronic migraine days in adults, suggesting a new treatment option.

This study aims to evaluate the safety and efficacy of adding atogepant to onabotulinumtoxinA for chronic migraine treatment.
Conducted as a Phase 3, open-label, multicenter study over 24 weeks.
Included 75 participants on a stable dose of onabotulinumtoxinA.
Participants received 60 mg of add-on atogepant once daily and underwent efficacy and safety evaluations.
65.3% of participants experienced at least one treatment-emergent adverse event.
Mean monthly migraine days reduced significantly from baseline by up to -7.20 days across 24 weeks.
54.2% and 61.9% of participants achieved a ≥50% reduction in migraine days at Weeks 1-12 and 13-24, respectively.

Rothrock et al. (2026) studied this question.

View Full Paper

Ask AI

Bookmark

April 10, 2026Cephalalgia

View Full Paper

Ask AI

Bookmark

Authors

Phase 3 open-label study shows combined therapy reduces chronic migraine days in adults, suggesting a new treatment option.

This study aims to evaluate the safety and efficacy of adding atogepant to onabotulinumtoxinA for chronic migraine treatment.
Conducted as a Phase 3, open-label, multicenter study over 24 weeks.
Included 75 participants on a stable dose of onabotulinumtoxinA.
Participants received 60 mg of add-on atogepant once daily and underwent efficacy and safety evaluations.
65.3% of participants experienced at least one treatment-emergent adverse event.
Mean monthly migraine days reduced significantly from baseline by up to -7.20 days across 24 weeks.
54.2% and 61.9% of participants achieved a ≥50% reduction in migraine days at Weeks 1-12 and 13-24, respectively.

Rothrock et al. (2026) studied this question.

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

View Full Paper

Ask AI

Bookmark